Lexaria Bioscience (LEXX) Depreciation & Amortization - Total (2017 - 2021)

Lexaria Bioscience has disclosed Depreciation & Amortization - Total across 5 years of filings, most recently posting $27929.0 for Q2 2021.

• Depreciation & Amortization - Total for Q2 2021 came in at $27929.0, down 0.54% year-over-year; the trailing twelve-month figure through Feb 2022 was $27929.0 (down 75.24% YoY), and the FY2020 annual result was $112750.0, up 86.21% from the prior year.
• Depreciation & Amortization - Total came in at $27929.0 for Q2 2021 at Lexaria Bioscience, roughly flat from $27930.0 in the prior quarter.
• In the past five years, Depreciation & Amortization - Total ranged from a high of $28875.0 in Q3 2020 to a low of $375.0 in Q4 2017.
• The 5-year median for Depreciation & Amortization - Total is $26195.0 (2019), against an average of $17293.0.
• Across the five-year window, Depreciation & Amortization - Total surged 4200.95% in 2019 and dropped 1.24% in 2021, its largest moves.
• Lexaria Bioscience's Depreciation & Amortization - Total stood at $375.0 in 2017, then jumped by 327.47% to $1603.0 in 2018, then jumped by 1616.28% to $27512.0 in 2019, then grew by 1.52% to $27929.0 in 2020, then changed by 0.0% to $27929.0 in 2021.
• The last three Depreciation & Amortization - Total figures came in at $27929.0 (Q2 2021), $27930.0 (Q1 2021), and $27929.0 (Q4 2020), per Business Quant data.